Veille Pharma
20.7K views | +0 today
Veille Pharma
Chargé d'affaires chez Patientsworld. Mes posts n'engagent que moi.
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

In Memory Of Steve Jobs, Novartis Pushes iPad // Pharmalot

In Memory Of Steve Jobs, Novartis Pushes iPad // Pharmalot | Veille Pharma | Scoop.it

Earlier this year, Novartis ceo Joe Jimenez wrote a memo to employees in which he enthused that the Apple iPad offers the drugmaker “game-changing” technology that will make it possible for sales reps to save 250 hours over the course of the year and allow “the entire field force to make an incredible 35,000 additional customer visits each year” (back story).


more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Pfizer Halts Lyrica Epilepsy Study

Pfizer Halts Lyrica Epilepsy Study | Veille Pharma | Scoop.it

Pfizer terminated a clinical trial of its drug Lyrica because interim results suggested the drug was effective as a stand-alone treatment for seizures in epilepsy patients.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Sanofi: résultats positifs pour son médicament expérimental Teriflunomide dans la SEP MyPharma Editions | L'Info Industrie & Politique de Santé

Sanofi: résultats positifs pour son médicament expérimental Teriflunomide dans la SEP MyPharma Editions | L'Info Industrie & Politique de Santé | Veille Pharma | Scoop.it

Le groupe pharmaceutique Sanofi et sa filiale Genzyme annoncent aujourd’hui la publication, dans le New England Journal of Medicine (NEJM), des résultats de l’étude pivot de Phase III TEMSO évaluant teriflunomide, un nouveau médicament oral expérimental administré une fois par jour dans le traitement de la sclérose en plaques.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Safety and Effectiveness of Rituximab in Patients with Rheumatoid Arthritis Following an Inadequate Response to 1 Prior Tumor Necrosis Factor Inhibitor: The RESET Trial

RTX was well tolerated, with a low incidence of infusion reactions and infections. Efficacy results, including enhanced response in rheumatoid factor-positive patients, were comparable to those reported in the literature. Based on its efficacy and safety profile and retreatment schedule, RTX is an attractive treatment option for patients that have not responded to a single TNF-α inhibitor.


more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Pfizer sets licensing deal with Puma Biotechnology

NEW YORK -- Pfizer said Wednesday it entered a licensing agreement with Puma Biotechnology for the development and marketing of neratinib, an experimental drug that has shown promise in treating a subset of breast cancer patients.


more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation

Although only 26% of patients had complete viral suppression at the time of transplant, 91% lost HBsAg, with 98.8% achieving undetectable levels of HBV DNA. A hepatitis B immunoglobulin–free regimen of entecavir monotherapy is effective after liver transplantation for chronic hepatitis B.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

La pharmacie mondiale va bientôt achever sa mutation

La pharmacie mondiale va bientôt achever sa mutation | Veille Pharma | Scoop.it

La stratégie de diversification par acquisitions entreprise par les grands laboratoires va leur permettre d’absorber le choc brevetaire et d’offrir un modèle de développement plus solide, indépendant de quelques médicaments vedettes.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Merck Serono et Ono Pharmaceutical signent deux accords dans les domaines de la sclérose en plaques et de l’oncologie

Merck Serono et Ono Pharmaceutical signent deux accords dans les domaines de la sclérose en plaques et de l’oncologie | Veille Pharma | Scoop.it

Merck Serono, la division biopharmaceutique de Merck KGaA a annoncé aujourd'hui la signature de deux accords distincts avec le japonais Ono Pharmaceutical pour renforcer ses activités dans les domaines de la sclérose en plaques et de l'oncologie.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor

WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Merck (NYSE:MRK - News), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA - News), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for ridaforolimus, an investigational oral mTOR inhibitor under development for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy. The FDA assigned a Standard review classification to this application.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Novo Nordisk, leader mondial des insulines modernes s’attaque avec la demande d’enregistrement de Degludec à Lantus de Sanofi, un enjeu de 4,7 milliards de dollars

Novo Nordisk, leader mondial des insulines modernes s’attaque avec la demande d’enregistrement de Degludec à Lantus de Sanofi, un enjeu de 4,7 milliards de dollars | Veille Pharma | Scoop.it

Le groupe pharmaceutique Danois Novo Nordisk a déposé une demande d’enregistrement aux Etats-Unis et en Europe pour Degludec, une insuline à longue durée d’action développée pour le traitement du diabète de type 1 et de type 2.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma.

Conclusion: In conclusion, dose-reduced lenalidomide is an effective and well tolerated treatment for patients with recurrent or refractory MM who cannot tolerate full doses.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

La Loi médicament votée à l'assemblée

L'Assemblée a adopté le projet de loi renforçant la sécurité du médicament, présenté par le gouvernement après le scandale du Mediator. Les députés ont peu modifié le texte.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Study finds early potential in GSK leukaemia drug

Study finds early potential in GSK leukaemia drug | Veille Pharma | Scoop.it

n a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

New Drugs to Prevent Strokes

Medical researchers are usually so cautious about characterizing results that when sober cardiologists use phrases like “very excited” and “a home run” and even “a new era,” you pay attention.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Les médecins aussi doutent des médicaments

Les médecins aussi doutent des médicaments | Veille Pharma | Scoop.it

Les résultats du sondage exclusif L'Express/CompuGroup Medical révèlent que les patients ne sont pas les seuls à perdre confiance dans les traitements prescrits. Les praticiens aussi.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Addition Of Doxil To Velcade Improves Treatment Outcomes For Multiple Myeloma Patients

Addition Of Doxil To Velcade Improves Treatment Outcomes For Multiple Myeloma Patients | Veille Pharma | Scoop.it

European researchers found that the addition of Doxil to Velcade significantly extends the time to disease progression in relapsed / refractory multiple myeloma patients, regardless of age, number of previous therapies, disease stage, and resistance to previous therapy.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors

Gilead and Boehringer Ingelheim Sign License Agreement for Novel HIV Non-Catalytic Integrase Inhibitors | Veille Pharma | Scoop.it

Gilead Sciences, Inc. (Nasdaq:GILD) and Boehringer Ingelheim today announced that the companies have entered into a licensing agreement, under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV. This includes the lead compound BI 224436, which has been evaluated in a Phase 1a dose-escalation study to assess bioavailability and pharmacokinetics in healthy volunteers.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Medical News: Parsing Rivaroxaban Data Raises Efficacy Questions - in Cardiovascular, Strokes from MedPage Today

Medical News: Parsing Rivaroxaban Data Raises Efficacy Questions - in Cardiovascular, Strokes from MedPage Today | Veille Pharma | Scoop.it

Whether rivaroxaban (Xarelto) is noninferior to warfarin for preventing stroke in patients with atrial fibrillation could depend on how you read the data, two physicians charge.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

L'avenir de l'industrie pharmaceutique est en dehors du médicament

L'avenir de l'industrie pharmaceutique est en dehors du médicament | Veille Pharma | Scoop.it

La maîtrise des nouvelles formes de communication et la création de services doivent être au cœur des préoccupations des spécialistes de la santé. Pour y parvenir, les entreprises du secteur doivent aller chercher la connaissance en dehors de leur écosystème.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Onyx Pharma submits NDA for carfilzomib in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced that it has completed the New Drug Application (NDA) submission to the US Food and Drug Administration (US FDA) under the accelerated approval process for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. In addition, Onyx has requested priority review of the application, which reduces the time the US FDA takes to review a new drug application.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Chez Sanofi, la reconstruction de la recherche sera longue

PARIS (Reuters) – Sanofi doit étoffer son portefeuille de médicaments pour pouvoir se hisser à des niveaux de valorisation comparables à ses pairs, mais il lui faudra du temps, estiment des analystes.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Brilique, l’anticoagulant de nouvelle génération d’Astra Zeneca obtient un remboursement en Allemagne selon le nouveau système d’évaluation des prix des médicaments.

Brilique, l’anticoagulant de nouvelle génération d’Astra Zeneca obtient un remboursement en Allemagne selon le nouveau système d’évaluation des prix des médicaments. | Veille Pharma | Scoop.it

Le groupe britannique Astra Zeneca a obtenu une approbation pour le prix de son anticoagulant de nouvelle génération par le Ministère de la santé en Allemagne, selon le nouveau système de fixation des prix en vigueur depuis le premier janvier 2011.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

FDA warns of Avastin's risk of infertility in women

FDA warns of Avastin's risk of infertility in women | Veille Pharma | Scoop.it

US regulators have updated the label of Roche's Avastin (bevaicuzumab) to warn about the possible risk of infertility in some women taking the cancer drug. The FDA said that the product's label effective September 30 now includes a warning regarding “ovarian failure” and recommended that doctors inform women of child-bearing age of the risk.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Baromètre santé 2011 Les soins de santé en Europe et aux Etats-Unis

30/09/2011 - Le « Baromètre Cercle Santé – Europ Assistance » décrypte les pratiques, attentes et préoccupations en matière de santé des citoyens de neuf pays européens et des États-Unis. Depuis 5 ans, il suit l'état de l'opinion sur les grands débats de santé.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

As maintenance therapy in locally advanced or metastatic NSCLC, pemetrexed is no longer restricted to only follow specific combinations of platinum-based chemotherapy

On 22 September 2011, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product pemetrexed (Alimta). The marketing authorization holder for this medicinal product is Eli Lilly Nederland B.V. They may request a re examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

more...
No comment yet.